Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHA1813 in Advanced Solid Tumors
NCT06682611Phase 2Not yet recruiting
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of SYHA1813 in solid tumor and metastatic solid tumor (6 arms), sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Primary endpoints: Dose Limiting Toxicity, Treatment-Emergent Adverse Events and Serious Adverse Events and 2 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
SYHA1813
03
Conditions
solid tumormetastatic solid tumor
Beyond the preview
Go deeper on NCT06682611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682611.